10 Results for "

Surface plasmon resonance (SPR)

" in MedChemExpress (MCE) Product Catalog:
Products (10)

10 Results for "Surface plasmon resonance (SPR)" in MCE Product Catalog:

22
22 Cited Publications
Cat. No.: HY-101533
CAS No.: 2143061-81-6
Purity:  99.79%
Target:  

Bcl-2 Family

Research Areas:  

Cancer

AZD-5991 is a potent and selective Mcl-1 inhibitor with an IC50 of 0.7 nM in FRET assay and a Kd of 0.17 nM in surface plasmon resonance (SPR) assay .
loading...
    loading...
4
4 Cited Publications
Cat. No.: HY-13963
CAS No.: 587841-73-4
Purity:  98.49%
ZCL278 is a selective Cdc42 inhibitor with Kds of 6.4 μM in fluorescence titration and 11.4 μM in surface plasmon resonance (SPR) measurement. ZCL278 is able to disrupt the Cdc42-ITSN interaction as well as GTP/GDP binding. ZCL278 has inhibitory effects on various enveloped viruses, but is ineffective against non-enveloped viruses. ZCL278 can be used for the studies of arsenic neurotoxicity and HER2-positive gastric cancer (GC) .
loading...
    loading...
Cat. No.: HY-160477
CAS No.: 300713-88-6
Target:  

PIKfyve NF-κB IKK

Research Areas:  

Inflammation/Immunology

DC-SX029 is a potent SNX10 protein-protein interaction (PPI) inhibitor with oral activity with an estimated KD constant of ~0.935 μM by surface plasmon resonance (SPR). DC-SX029 blocks the SNX10-PIKfyve interaction, thereby decreased the TBK1/c-Rel signaling activation. DC-SX029 does not affect the protein level of SNX10. DC-SX029 has the potential for inflammatory bowel disease (IBD) research .
loading...
    loading...
Cat. No.: HY-101533B
CAS No.: 2143061-82-7
Purity:  99.83%
Target:  

Bcl-2 Family

Research Areas:  

Cancer

AZD-5991 S-enantiomer is the less active enantiomer of AZD-5991. AZD-5991 S-enantiomer is a Mcl-1 inhibitor with an IC50 of 6.3 μM in FRET assay and a Kd of 0.98 μM in surface plasmon resonance (SPR) assay.
loading...
    loading...
Cat. No.: HY-160481
CAS No.: 2567913-75-9
Target:  

Tau Protein MicroRNA

Research Areas:  

Neurological Disease

MG-1102 is first-in-class dual binder of monomeric tau and pre-miRNA-146a. MG-1102 shows specific inhibition of miRNA146a with IC50s of 0.21 mM and 0.36 mM specific inhibition of doublelabeled pre-miRNA146a and mono-labeled pre-miRNA146a, respectively. MG-1102 interacts with tau monomers with a Kd of 3.21 mM by surface plasmon resonance (SPR). MG-1102 is a potential multi-target-directed ligands (MTDLs) for Alzheimer’s disease (AD) .
loading...
    loading...
Cat. No.: HY-W003471
CAS No.: 159326-68-8
Target:  

MAP4K

Research Areas:  

Others

Pyrrolo[2,1-f][1,2,4]triazin-4-amine is a MAP4K4 inhibitor with a surface plasmon resonance (SPR) Kd of 88 μM and a ligand efficiency of 0.56 .
loading...
    loading...
Cat. No.: HY-101533R
CAS No.: 2143061-81-6
Research Areas:  

Cancer

AZD-5991 (Standard) is the analytical standard of AZD-5991 (HY-101533). This product is intended for research and analytical applications. AZD-5991 is a potent and selective Mcl-1 inhibitor with an IC50 of 0.7 nM in FRET assay and a Kd of 0.17 nM in surface plasmon resonance (SPR) assay .
loading...
    loading...
Cat. No.: HY-181685
Target:  

LAG-3 TNF Receptor

Research Areas:  

Cancer

LAGi-DEL is a LAG-3 inhibitor, with Kd values of 97.33 nM and 271 nM in surface plasmon resonance (SPR) assay and microscale thermophoresis (MST) assay, respectively. LAGi-DEL blocks the LAG-3/MHC-II interaction, with an EC50 of 138 nM. LAGi-DEL restores T cell activation, enhances IFN-γ secretion and promotes immune-mediated cytotoxicity. LAGi-DEL can be used in the research of acute myeloid leukemia, lung cancer and melanoma .
loading...
    loading...
Cat. No.: HY-180766
Target:  

JAK

Research Areas:  

Cancer

JAK2-IN-19 (Compound 3p) is a JAK2 inhibitor with a KD value of 1.11 μM. JAK2-IN-19 inhibits the proliferation of K562 cells and HeLa cells. JAK2-IN-19 significantly reduces the level of p-JAK2. JAK2-IN-19 can be used for research on cervical cancer and leukemia .
loading...
    loading...
Cat. No.: HY-13963S
ZCL278- 13C is a 13C-labeled version of ZCL278 (HY-13963). ZCL278 is a selective Cdc42 inhibitor with Kds of 6.4 μM in fluorescence titration and 11.4 μM in surface plasmon resonance (SPR) measurement. ZCL278 can disrupt the interaction between Cdc42 and ITSN, and also inhibit the binding of GTP and GDP. ZCL278 has inhibitory effects on various enveloped viruses, but is ineffective against non-enveloped viruses. ZCL278 can be used in the research of arsenic neurotoxicity and HER2-positive gastric cancer (GC) [1][2][3][4].
loading...
    loading...